Paul A. Mahon Sells 7,700 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,743,122.70. The trade was a 17.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Stock Down 1.3 %

Shares of United Therapeutics stock opened at $369.67 on Friday. The firm has a market capitalization of $16.51 billion, a P/E ratio of 16.23, a P/E/G ratio of 1.09 and a beta of 0.54. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The firm’s 50 day moving average is $369.14 and its two-hundred day moving average is $339.06.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same period last year, the business earned $5.38 EPS. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, research analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Oddo BHF Asset Management Sas purchased a new position in United Therapeutics during the 3rd quarter worth approximately $1,698,000. Franklin Resources Inc. grew its position in shares of United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after acquiring an additional 123,929 shares during the last quarter. Tri Ri Asset Management Corp acquired a new position in shares of United Therapeutics in the 3rd quarter valued at $7,686,000. Tidal Investments LLC raised its position in United Therapeutics by 33.1% in the 3rd quarter. Tidal Investments LLC now owns 11,272 shares of the biotechnology company’s stock valued at $4,039,000 after purchasing an additional 2,803 shares during the last quarter. Finally, World Investment Advisors LLC acquired a new stake in United Therapeutics during the 3rd quarter worth $393,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Argus lifted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. Finally, LADENBURG THALM/SH SH boosted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.